What do the trials actually say — and why did the biggest claim fail?
CoQ10's evidence arc is the supplement field's most instructive rise-and-correction: a mechanism so fundamental it generated confident predictions across cardiology (statin myopathy) that the trials then failed, alongside genuine positive signals (heart failure adjunct, blood pressure modesty) that survived because they were tested honestly. This chapter reads both — the null that corrected the syllogism, and the positives that earned their modest grades.
The field teaches the syllogism lesson at grand scale:
Frederick Crane isolates the yellow compound from beef-heart mitochondria at Wisconsin — the heart, as always, the source.
The Merck chemist (later a B12 and CoQ10 champion) determines CoQ10's full structure — quinone head, ten-unit tail — and the synthesis follows.
The proton-gradient theory of ATP production — CoQ10's role as the electron shuttle written into science's most stubbornly defended hypothesis.
Mitchell's Nobel Prize — the rejected theory now the foundation, CoQ10's mechanism central to the accepted picture.
Japan's regulatory system approves CoQ10 for heart failure — the only market where the molecule is a prescription medicine rather than a shelf item.
The randomized 300 mg/day heart-failure adjunct trial — fewer adverse events, better NYHA class — the modern evidence era's anchor, awaiting confirmation.
The statin-myopathy nulls reshape the claims; the adjunct positives hold their modest ground; and the molecule settles into its honest size — fundamental biology, adjunct-sized effects.
POPULATION · 420 patients with moderate-to-severe heart failure, 300 mg CoQ10 (ubiquinone) daily vs. placebo, 2 years
FINDING · Fewer major adverse cardiovascular events and lower cardiac mortality in the CoQ10 arm — added to full guideline therapy — with improved NYHA functional class.
LIMITATION · Modest sample with early termination; the confirmatory large trial the field needs has not yet run. An encouraging adjunct signal, honestly graded as promising-pending-confirmation.
POPULATION · Patients with statin-associated muscle symptoms, CoQ10 vs. placebo across the best-designed trials
FINDING · No significant improvement in muscle pain versus placebo — the mechanism-predicted benefit failing at the outcome level.
LIMITATION · The null is the finding: heterogeneity in symptom definition and small samples complicate pooling, but the best-designed trials point the same direction. The aisle's biggest claim, corrected by its own trials.
POPULATION · 42 adults with migraine, 100 mg three times daily, 3 months
FINDING · 47.6% of the CoQ10 group achieved ≥50% attack reduction vs. 14.4% on placebo — the mitochondrial-hypothesis trio's third leg.
LIMITATION · Small sample, early termination weakening statistical power — one positive trial defines the entire migraine evidence base. Our migraine page grades it Tier 3: promising, single-trial territory.
POPULATION · Human tissue analyses across the biochemistry literature
FINDING · Heart tissue carries the body's highest CoQ10 concentrations; tissue levels decline with age — the two observations anchoring the cardiac and aging claims.
LIMITATION · Descriptive biochemistry — concentrations and declines are facts, not endpoints. They generate hypotheses (the heart-failure, statin, and anti-aging stories) that the trials then test, with the mixed record this page grades.
POPULATION · Statin-treated patients across measurement studies
FINDING · Statins reliably reduce plasma CoQ10 levels — the shared mevalonate-pathway mechanism confirmed in the blood compartment.
LIMITATION · The depletion is the fact; whether it matters clinically is the statin-myopathy question the outcome trials answered mostly null. Blood level, once again, is a surrogate — the field's calibration in one molecule.